Expert Series: Dr Chun Fong on finding the keys to unlock AML
Dr Chun Fong believes that testing for minimal residual disease (MRD) is part of the answer.
- Acute myeloid leukaemia
- Interviews with experts
- Research
Dr Chun Fong believes that testing for minimal residual disease (MRD) is part of the answer.
Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.
Trish Wilson has "always been drawn to working in areas where loss has been an underlying issue”.
Dr Devendra Hiwase thinks every patient with this rare form of blood cancer should have molecular profiling.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
Dr Rishi Kotecha talks about the revolutionary treatments which are improving outcomes for babies and children with high-risk leukaemia.
Dr Forsyth is passionate about what MPN patients can do to improve their health.
Dr Gibbs discusses everything from the incidence, diagnosis and treatment of amyloidosis, to supportive care, quality of life, and how he came to specialise in this field.
Professor Susan Branford’s work has underpinned many Australian and internationally significant developments in CML over the last 20 years.
Dr Daniel Thomas brought us up-to-speed on his multi-faceted work in the field of myeloid leukaemia.